2015 American Transplant Congress
Impact of Anti-CMV Prophylactic Therapy on the Development of CMV Quantiferon Sero-Conversion in High-Risk Patients
Transplant Surgery, Medical University of South Carolina, Charleston, SC.
Body: Abdominal organ transplants at high risk for CMV infection (D+/R) remain a difficult cohort to prevent late CMV infection despite prolonged valganciclovir (VGC) administration.…2015 American Transplant Congress
Does Prophylaxis Strategy Matter? CMV Reactivation in Moderate Risk (R+) Heart Transplant Recipients
Pharmacy, Tampa General Hospital, Tampa, FL.
Purpose: CMV is a significant complication in heart transplant recipients (HTR). Little evidence exists to guide prophylaxis in moderate risk (R+) patients.Methods: An IRB-approved review…
- « Previous Page
- 1
- …
- 31
- 32
- 33